Prosthetic Foot Adaptability for Amputation
Trial Summary
What is the purpose of this trial?
People with lower extremity amputation (LEA) have persistent problems with balance, falls, residual limb pain, functional mobility, cognitive attention during gait, and satisfaction with participation in daily activities, despite using prostheses. The purpose of this randomized clinical trial is to advance understanding of how dynamic foot design features may help people with LEA This study will include people with above-knee amputations, or with bilateral amputations, or with below-knee amputations and lower levels of mobility. The main study questions/goals are: 1a) To determine if frontal plane adaptation in a foot prosthesis impacts performance, comfort, activities of daily living, and community mobility in the study populations. To answer this question, we will compare a locked and unlocked version of the novel prosthesis. 1b) To determine how the unlocked investigational foot condition compares to the person's usual foot using the outcomes listed above. 2) To examine the participants' lived experience during community activities. The study will use performance tests, questionnaires, logbooks, and interviews to monitor person-centered outcomes and perceptions of personal functioning during the use of the investigational foot (locked and unlocked) compared to the person's usual foot.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on prosthetic foot use, so it's best to discuss your medications with the trial team.
What data supports the effectiveness of the treatment META-Arc foot for amputation?
How does the META-Arc foot treatment differ from other prosthetic foot options for amputees?
The META-Arc foot is unique because it features a polycentric ankle joint that allows for more natural movement in the frontal plane, making it easier for users to walk on uneven terrain. This adaptability is not typically found in other prosthetic feet, which often have limited movement and can make walking on uneven surfaces challenging.678910
Research Team
Murray Maitland, PT, PhD
Principal Investigator
University of Washington
Eligibility Criteria
This trial is for individuals with above-knee amputations, bilateral amputations, or below-knee amputations who have lower mobility levels. It aims to help them with balance, pain, and daily activities by testing a new type of foot prosthesis.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
A1 Phase
Participants use their usual prosthetic foot and complete baseline assessments
B1 Phase
Participants use the investigational foot with either locked or unlocked linkage and perform community activities
B2 Phase
Participants continue using the investigational foot with the opposite linkage condition and perform community activities
A2 Phase
Participants return to using their usual prosthetic foot and reflect on differences
Follow-up
Participants are monitored for safety and effectiveness after the trial phases
Treatment Details
Interventions
- META-Arc foot locked (Prosthesis)
- META-Arc foot unlocked (Prosthesis)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Washington
Lead Sponsor
Dr. Timothy H. Dellit
University of Washington
Chief Executive Officer since 2023
MD from University of Washington
Dr. Anneliese Schleyer
University of Washington
Chief Medical Officer since 2023
MD, MHA
United States Department of Defense
Collaborator
Pete Hegseth
United States Department of Defense
Chief Executive Officer
Bachelor's degree in Political Science from Princeton University, JD from Harvard Law School
Lisa Hershman
United States Department of Defense
Chief Medical Officer since 2021
MD from Uniformed Services University of the Health Sciences